Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene

PLoS ONE

Volumn 12, Issue 7, 2017, Pages

  Sabet, Salwa ^a   George, Marina A ^b   El Shorbagy, Haidan M ^a   Bassiony, Heba ^a   Farroh, Khaled Y ^c   Youssef, Tareq ^b   Salaheldin, Taher A ^c,d  

^a CAIRO UNIVERSITY   (Egypt)

^b Cairo University   (Egypt)

^c PLANT PATHOLOGY RESEARCH INSTITUTE   (Egypt)

^d The British University in Egypt   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; HEPATITIS VACCINE; NANOPARTICLE; NONSTRUCTURAL PROTEIN 2; NS2 PROTEIN, HEPATITIS C VIRUS; RECOMBINANT PROTEIN; VIRAL PROTEIN;

ANTIGENICITY; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; DISPERSITY; DRUG CONJUGATION; ESCHERICHIA COLI; GENE EXPRESSION; GENE STRUCTURE; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 4A; NONHUMAN; NS2 GENE; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; X RAY DIFFRACTION; ZETA POTENTIAL; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMAN; IMMUNOLOGY; METABOLISM; PROCEDURES; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; ULTRAVIOLET SPECTROPHOTOMETRY; VIROLOGY;

DRUG DELIVERY SYSTEMS; GELATIN; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY, ULTRAVIOLET; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS; X-RAY DIFFRACTION;

EID: 85026205733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0181723     Document Type: Article

References (38)

1. Esmat G. Hepatitis C in the Eastern Mediterranean Region. East Mediterr Health J. 2013; 19(7):587–8. PMID: 24975301
2. Elkady A, Tanaka Y, Kurbanov F, Sugauchi F, Sugiyama M, Khan A, et al. Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication. J Med Virol. 2009; 81(6):1015–23. Epub 2009/04/22. https://doi.org/10.1002/jmv.21492 PMID: 19382263
3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13(17):2436–41. https://doi.org/10.3748/wjg.v13.i17.2436 PMID: 17552026
4. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007; 42 (7):513–21. https://doi.org/10.1007/s00535-007-2064-6 PMID: 17653645
5. D’Ambrosio R, Colombo M. Should surveillance for liver cancer be modified in hepatitis c patients after treatment-related cirrhosis regression? Liver Int. 2016. https://doi.org/10.1111/liv.13106 PMID: 26936383
6. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005; 54(6):858–66. https://doi.org/10.1136/gut.2004.057182 PMID: 15888797
7. Bhatti Z, Berenson CS. Adult systemic cat scratch disease associated with therapy for hepatitis C. BMC Infect Dis. 2007; 7:8. https://doi.org/10.1186/1471-2334-7-8 PMID: 17319959
8. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME, et al. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat. 2007; 14(3):213–20. https://doi.org/10.1111/j.1365-2893.2006.00795.x PMID: 17305887
9. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int. 2008; 28(8):1112–9. https://doi.org/10.1111/j.1478-3231.2008.01750.x PMID: 18397226
10. Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015; 63(3):581–5. https://doi.org/10.1016/j.jhep.2015.04.023 PMID: 25937436
11. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000; 31 (3):777–82. https://doi.org/10.1002/hep.510310332 PMID: 10706572
12. Gorzin Z, Gorzin AA, Tabarraei A, Behnampour N, Irani S, Ghaemi A. Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL/6 mice. Iran Biomed J. 2014; 18(1):1–7. https://doi.org/10.6091/ibj.1231.2013 PMID: 24375156
13. Dumoulin FL, von dem Bussche A, Li J, Khamzina L, Wands JR, Sauerbruch T, et al. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology. 2003; 305(2):260–6. PMID: 12573571
14. Jirasko V, Montserret R, Lee JY, Gouttenoire J, Moradpour D, Penin F, et al. Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. PLoS Pathog. 2010; 6(12):e1001233. https://doi.org/10.1371/journal.ppat.1001233 PMID: 21187906
15. Popescu C-I, Callens N, Trinel D, Roingeard P, Moradpour D, Descamps V, et al. NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog. 2011; 7(2):e1001278. https://doi.org/10.1371/journal.ppat.1001278 PMID: 21347350
16. Gorzin AA, Ramsland PA, Tachedjian G, Gowans EJ. Identification of residues involved in NS2 homodimerization and elucidation of their impact on the HCV life cycle. J Viral Hepat. 2012; 19(3):189–98. https://doi.org/10.1111/j.1365-2893.2011.01504.x PMID: 22329373
17. Lorenz IC. The Hepatitis C Virus Nonstructural Protein 2 (NS2): An Up-and-Coming Antiviral Drug Target. Viruses. 2010; 2(8):1635–46. https://doi.org/10.3390/v2081635 PMID: 21994698
18. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 1993; 53(5):962–7. PMID: 8439971
19. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990; 247(4949 Pt 1):1465–8. PMID: 1690918
20. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet. 2005; 54:3–20. https://doi.org/10.1016/S0065-2660(05)54001-X PMID: 16096005
21. Lehrman S. Virus treatment questioned after gene therapy death. Nature. 1999; 401(6753):517–8. https://doi.org/10.1038/43977 PMID: 10524611
22. Sun JY, Anand-Jawa V, Chatterjee S, Wong KK. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther. 2003; 10(11):964–76. https://doi.org/10.1038/sj.gt.3302039 PMID: 12756417
23. Choi YS, Lee MY, David AE, Park YS. Nanoparticles for gene delivery: therapeutic and toxic effects. Mol Cell Toxicol. 2014; 10(1):1–8. https://doi.org/10.1007/s13273-014-0001-3
24. Young S, Wong M, Tabata Y, Mikos AG. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. Journal of Controlled Release. 2005; 109(1–3):256–74. https://doi.org/10.1016/j.jconrel.2005.09.023 PMID: 16266768
25. Ofokansi K, Winter G, Fricker G, Coester C. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. Eur J Pharm Biopharm. 2010; 76(1):1–9. https://doi.org/10.1016/j.ejpb.2010.04.008 PMID: 20420904
26. Coester CJ, Langer K, van Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation—a new preparation method, surface modifications and cell uptake. J Microencapsul. 2000; 17(2):187–93. https://doi.org/10.1080/026520400288427 PMID: 10738694
27. Kramer MF, Coen DM. Enzymatic amplification of DNA by PCR: standard procedures and optimization. Curr Protoc Mol Biol. 2001; Chapter 15:Unit-15.1. https://doi.org/10.1002/0471142727.mb1501s56PMID: 18265115
28. Foox M, Zilberman M. Drug delivery from gelatin-based systems. Expert Opin Drug Deliv. 2015; 12 (9):1547–63. https://doi.org/10.1517/17425247.2015.1037272 PMID: 25943722
29. Su K, Wang C. Recent advances in the use of gelatin in biomedical research. Biotechnol Lett. 2015; 37 (11):2139–45. https://doi.org/10.1007/s10529-015-1907-0 PMID: 26160110
30. Shiehzadeh F, Tafaghodi M. Dry powder form of polymeric nanoparticles for pulmonary drug delivery. Curr Pharm Des. 2016.
31. Brzoska M, Langer K, Coester C, Loitsch S, Wagner TO, Mallinckrodt C. Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochemical and biophysical research communications. 2004; 318(2):562–70. Epub 2004/05/04. https://doi.org/10.1016/j.bbrc.2004.04.067 PMID: 15120637
32. Jahanshahi M, Sanati MH, Babaei Z. Optimization of parameters for the fabrication of gelatin nanoparticles by the Taguchi robust design method. Journal of Applied Statistics. 2008; 35(12):1345–53. https://doi.org/10.1080/02664760802382426
33. Jahanshahi M, Sanati MH, Hajizadeh S, Babaei Z. Gelatin nanoparticle fabrication and optimization of the particle size. physica status solidi (a). 2008; 205(12):2898–902. https://doi.org/10.1002/pssa.200824329
34. Tseng C-L, Chen K-H, Su W-Y, Lee Y-H, Wu C-C, Lin F-H. Cationic Gelatin Nanoparticles for Drug Delivery to the Ocular Surface:In VitroandIn VivoEvaluation. Journal of Nanomaterials. 2013; 2013:1–11. https://doi.org/10.1155/2013/238351
35. Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, et al. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharmaceutical research. 2008; 25(3):551–62. Epub 2007/10/04. https://doi.org/10.1007/s11095-007-9410-5PMID: 17912489
36. Jadhav NR, Tone JS, Irny PV, Nadaf SJ. Development and characterization of gelatin based nanoparticles for targeted delivery of zidovudine. International journal of pharmaceutical investigation. 2013; 3 (3):126–30. Epub 2013/10/30. https://doi.org/10.4103/2230-973X.119213 PMID: 24167784
37. Truong-Le VL, August JT, Leong KW. Controlled gene delivery by DNA-gelatin nanospheres. Hum Gene Ther. 1998; 9(12):1709–17. https://doi.org/10.1089/hum.1998.9.12-1709 PMID: 9721081
38. Hosseinkhani H, Abedini F, Ou K-L, Domb AJ. Polymers in gene therapy technology. Polymers for Advanced Technologies. 2015; 26(2):198–211. https://doi.org/10.1002/pat.3432